Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Parkinson disease (PD) is a neurodegenerative disorder characterized by motor deficits.
• Levodopa is a primary treatment for PD, but long-term use can cause levodopa-induced dyskinesia (LID).
• The dopamine D3 receptor's role in PD and LID is not fully understood.

Purpose of the Study:

• To investigate the role of the dopamine D3 receptor in MPTP-induced parkinsonism and levodopa-induced dyskinesia in a non-human primate model.
• To evaluate the therapeutic potential of D3 receptor-selective agents in managing LID.

Main Methods:

• MPTP administration to induce parkinsonism in monkeys.
• Assessment of D3 receptor expression.
• Administration of levodopa and D3 receptor modulators (partial agonist and antagonists).
• Evaluation of motor behavior and therapeutic effects.

Main Results:

• MPTP-induced parkinsonism was associated with decreased D3 receptor expression.
• Levodopa-induced dyskinesia (LID) was linked to D3 receptor overexpression.
• A D3 receptor partial agonist significantly reduced LID without compromising levodopa's therapeutic efficacy.
• D3 receptor antagonists attenuated LID but also reinstated PD-like symptoms.

Conclusions:

• The dopamine D3 receptor plays a dual role in both the therapeutic effects of levodopa and the development of LID.
• D3 receptor partial agonists show promise for normalizing D3 receptor function.
• This suggests a potential therapeutic strategy for managing LID and improving levodopa therapy in Parkinson disease patients.